JP2002538771A5 - - Google Patents

Download PDF

Info

Publication number
JP2002538771A5
JP2002538771A5 JP2000587730A JP2000587730A JP2002538771A5 JP 2002538771 A5 JP2002538771 A5 JP 2002538771A5 JP 2000587730 A JP2000587730 A JP 2000587730A JP 2000587730 A JP2000587730 A JP 2000587730A JP 2002538771 A5 JP2002538771 A5 JP 2002538771A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
monoclonal antibody
monoclonal
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2000587730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002538771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/030345 external-priority patent/WO2000035409A2/en
Publication of JP2002538771A publication Critical patent/JP2002538771A/ja
Publication of JP2002538771A5 publication Critical patent/JP2002538771A5/ja
Ceased legal-status Critical Current

Links

JP2000587730A 1998-12-16 1999-12-16 Hiv−1の融合及び付着の相乗的阻害、そのための組成物および抗体 Ceased JP2002538771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21279398A 1998-12-16 1998-12-16
US11253298P 1998-12-16 1998-12-16
US60/112,532 1998-12-16
US09/212,793 1998-12-16
PCT/US1999/030345 WO2000035409A2 (en) 1998-12-16 1999-12-16 Hiv-i fusion inhibition compounds

Publications (2)

Publication Number Publication Date
JP2002538771A JP2002538771A (ja) 2002-11-19
JP2002538771A5 true JP2002538771A5 (cg-RX-API-DMAC7.html) 2007-02-15

Family

ID=26810060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000587730A Ceased JP2002538771A (ja) 1998-12-16 1999-12-16 Hiv−1の融合及び付着の相乗的阻害、そのための組成物および抗体

Country Status (13)

Country Link
EP (2) EP1144006B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002538771A (cg-RX-API-DMAC7.html)
AT (1) ATE375802T1 (cg-RX-API-DMAC7.html)
AU (3) AU773175B2 (cg-RX-API-DMAC7.html)
CA (1) CA2355607A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107858T1 (cg-RX-API-DMAC7.html)
DE (1) DE69937369T2 (cg-RX-API-DMAC7.html)
DK (1) DK1144006T3 (cg-RX-API-DMAC7.html)
ES (1) ES2296416T3 (cg-RX-API-DMAC7.html)
HK (1) HK1041207B (cg-RX-API-DMAC7.html)
MX (1) MXPA01006097A (cg-RX-API-DMAC7.html)
PT (1) PT1144006E (cg-RX-API-DMAC7.html)
WO (1) WO2000035409A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041020A1 (en) 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
EP1456241B1 (en) * 2001-12-21 2005-03-16 Micromet AG Mono-and dual anti-cd4-rantes chemokine/cytokine constructs
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1478738B1 (en) * 2002-02-22 2008-11-12 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
WO2007085567A2 (en) * 2006-01-30 2007-08-02 F. Hoffmann-La Roche Ag Synergistic compositions for treating hiv
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
ATE550355T1 (de) 2006-09-29 2012-04-15 Hoffmann La Roche Antikörper gegen ccr5 und ihre verwendung
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3375697A (en) * 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
EP0956044A4 (en) * 1996-06-14 2005-01-05 Progenics Pharm Inc USES OF A CHEMOKIN RECEPTOR TO INHIBIT HIV-1 INFECTION
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Similar Documents

Publication Publication Date Title
US11987635B2 (en) Anti-4-1BB antibodies and methods of making and using thereof
JP2022031635A5 (cg-RX-API-DMAC7.html)
KR102100467B1 (ko) Cd33 항체 및 암을 치료하기 위한 이의 용도
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
JP6515111B2 (ja) 新規の抗クローディン抗体および使用方法
US8613903B2 (en) Humanized L243 antibodies
JP2020002172A5 (cg-RX-API-DMAC7.html)
JP2008540447A5 (cg-RX-API-DMAC7.html)
KR20160097336A (ko) 신규 항-dpep3 항체 및 이의 사용 방법
WO2015081158A1 (en) Method of treating hiv by disrupting pd-1/pd-l1 signaling
HRP20170342T1 (hr) Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
WO2022147532A1 (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
WO1991012023A2 (en) Hybrid reagents capable of selectively releasing molecules into cells
JP2013539352A5 (cg-RX-API-DMAC7.html)
EP4527408A3 (en) Claudin-6 antibodies and drug conjugates
JP2015523961A5 (cg-RX-API-DMAC7.html)
WO2002022077A3 (en) Compositions and methods for inhibition of hiv-1 infection
JP2016503067A5 (cg-RX-API-DMAC7.html)
EP4041763B1 (en) Pd1 and vegfr2 dual-binding agents
HRP20230027T1 (hr) Konjugati protutijela s lijekom i njihova upotreba u liječenju raka
JP2005505256A5 (cg-RX-API-DMAC7.html)
RU2017145662A (ru) Моноклональные антитела и способы их применения
CN110475787A (zh) 结合剂
EP3781201A1 (en) Antibodies for chelated radionuclides and clearing agents
JP2013519690A5 (cg-RX-API-DMAC7.html)